These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 38653501)
21. Application of a physiologically based pharmacokinetic model for the prediction of mirabegron plasma concentrations in a population with severe renal impairment. Konishi K; Minematsu T; Nagasaka Y; Tabata K Biopharm Drug Dispos; 2019 May; 40(5-6):176-187. PubMed ID: 30985942 [TBL] [Abstract][Full Text] [Related]
22. Optimizing the Clinical Use of Carvedilol in Liver Cirrhosis Using a Physiologically Based Pharmacokinetic Modeling Approach. Rasool MF; Khalil F; Läer S Eur J Drug Metab Pharmacokinet; 2017 Jun; 42(3):383-396. PubMed ID: 27313074 [TBL] [Abstract][Full Text] [Related]
23. Hepatic UDP-glucuronosyltransferase is responsible for eslicarbazepine glucuronidation. Loureiro AI; Fernandes-Lopes C; Bonifácio MJ; Wright LC; Soares-da-Silva P Drug Metab Dispos; 2011 Sep; 39(9):1486-94. PubMed ID: 21673130 [TBL] [Abstract][Full Text] [Related]
24. Interactions between human UDP-glucuronosyltransferase (UGT) 2B7 and UGT1A enzymes. Fujiwara R; Nakajima M; Oda S; Yamanaka H; Ikushiro S; Sakaki T; Yokoi T J Pharm Sci; 2010 Jan; 99(1):442-54. PubMed ID: 19475557 [TBL] [Abstract][Full Text] [Related]
25. Glucuronidation of a sarpogrelate active metabolite is mediated by UDP-glucuronosyltransferases 1A4, 1A9, and 2B4. Kim HJ; Jeong ES; Seo KA; Shin KJ; Choi YJ; Lee SJ; Ghim JL; Sohn DR; Shin JG; Kim DH Drug Metab Dispos; 2013 Aug; 41(8):1529-37. PubMed ID: 23704698 [TBL] [Abstract][Full Text] [Related]
26. Glucuronidation of the second-generation antipsychotic clozapine and its active metabolite N-desmethylclozapine. Potential importance of the UGT1A1 A(TA)₇TAA and UGT1A4 L48V polymorphisms. Erickson-Ridout KK; Sun D; Lazarus P Pharmacogenet Genomics; 2012 Aug; 22(8):561-76. PubMed ID: 22565219 [TBL] [Abstract][Full Text] [Related]
27. Involvement of human hepatic UGT1A1, UGT2B4, and UGT2B7 in the glucuronidation of carvedilol. Ohno A; Saito Y; Hanioka N; Jinno H; Saeki M; Ando M; Ozawa S; Sawada J Drug Metab Dispos; 2004 Feb; 32(2):235-9. PubMed ID: 14744946 [TBL] [Abstract][Full Text] [Related]
28. Correlation between UDP-glucuronosyltransferase genotypes and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone glucuronidation phenotype in human liver microsomes. Wiener D; Fang JL; Dossett N; Lazarus P Cancer Res; 2004 Feb; 64(3):1190-6. PubMed ID: 14871856 [TBL] [Abstract][Full Text] [Related]
29. Physiologically-based pharmacokinetic modeling for mirabegron: a multi-elimination pathway mediated by cytochrome P450 3A4, uridine 5'-diphosphate-glucuronosyltransferase 2B7, and butyrylcholinesterase. Konishi K; Minematsu T; Nagasaka Y; Tabata K Xenobiotica; 2019 Aug; 49(8):912-921. PubMed ID: 30301385 [TBL] [Abstract][Full Text] [Related]
30. Modulation of UDP-glucuronosyltransferase function by cytochrome P450: evidence for the alteration of UGT2B7-catalyzed glucuronidation of morphine by CYP3A4. Takeda S; Ishii Y; Iwanaga M; Mackenzie PI; Nagata K; Yamazoe Y; Oguri K; Yamada H Mol Pharmacol; 2005 Mar; 67(3):665-72. PubMed ID: 15611481 [TBL] [Abstract][Full Text] [Related]
32. Glucuronidation of Abiraterone and Its Pharmacologically Active Metabolites by UGT1A4, Influence of Polymorphic Variants and Their Potential as Inhibitors of Steroid Glucuronidation. Vaillancourt J; Turcotte V; Caron P; Villeneuve L; Lacombe L; Pouliot F; Lévesque É; Guillemette C Drug Metab Dispos; 2020 Feb; 48(2):75-84. PubMed ID: 31727674 [TBL] [Abstract][Full Text] [Related]
33. Involvement of multiple UDP-glucuronosyltransferase 1A isoforms in glucuronidation of 5-(4'-hydroxyphenyl)-5-phenylhydantoin in human liver microsomes. Nakajima M; Sakata N; Ohashi N; Kume T; Yokoi T Drug Metab Dispos; 2002 Nov; 30(11):1250-6. PubMed ID: 12386132 [TBL] [Abstract][Full Text] [Related]
34. Effects of a Novel UGT2B Haplotype and UGT1A4*3 Allele Variants on Glucuronidation of Clozapine In vivo. Smith RL; Wollmann BM; Kausberg M; Mæland S; Tveito M; O'Connell K; Molden E; Kringen MK Curr Drug Metab; 2022; 23(1):66-72. PubMed ID: 35105285 [TBL] [Abstract][Full Text] [Related]
35. Role of cytochrome P450 and UDP-glucuronosyltransferases in metabolic pathway of homoegonol in human liver microsomes. Kwon SS; Kim JH; Jeong HU; Ahn KS; Oh SR; Lee HS Drug Metab Pharmacokinet; 2015 Aug; 30(4):305-13. PubMed ID: 26163112 [TBL] [Abstract][Full Text] [Related]
36. Quaternary ammonium-linked glucuronidation of tamoxifen by human liver microsomes and UDP-glucuronosyltransferase 1A4. Kaku T; Ogura K; Nishiyama T; Ohnuma T; Muro K; Hiratsuka A Biochem Pharmacol; 2004 Jun; 67(11):2093-102. PubMed ID: 15135306 [TBL] [Abstract][Full Text] [Related]
37. Characterization of tamoxifen and 4-hydroxytamoxifen glucuronidation by human UGT1A4 variants. Sun D; Chen G; Dellinger RW; Duncan K; Fang JL; Lazarus P Breast Cancer Res; 2006; 8(4):R50. PubMed ID: 16884532 [TBL] [Abstract][Full Text] [Related]
38. Optimized assays for human UDP-glucuronosyltransferase (UGT) activities: altered alamethicin concentration and utility to screen for UGT inhibitors. Walsky RL; Bauman JN; Bourcier K; Giddens G; Lapham K; Negahban A; Ryder TF; Obach RS; Hyland R; Goosen TC Drug Metab Dispos; 2012 May; 40(5):1051-65. PubMed ID: 22357286 [TBL] [Abstract][Full Text] [Related]
39. In vitro characterization of belinostat glucuronidation: demonstration of both UGT1A1 and UGT2B7 as the main contributing isozymes. Dong D; Zhang T; Lu D; Liu J; Wu B Xenobiotica; 2017 Apr; 47(4):277-283. PubMed ID: 27180825 [TBL] [Abstract][Full Text] [Related]
40. Dynamically simulating the interaction of midazolam and the CYP3A4 inhibitor itraconazole using individual coupled whole-body physiologically-based pharmacokinetic (WB-PBPK) models. Vossen M; Sevestre M; Niederalt C; Jang IJ; Willmann S; Edginton AN Theor Biol Med Model; 2007 Mar; 4():13. PubMed ID: 17386084 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]